Enoxaparin is not an oral factor Xa inhibitor.: Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

Richard Buka; Pip Nicolson; David Sutton

doi:10.1007/s11239-024-02948-5

Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

Richard Buka^*, Pip Nicolson, David Sutton

^*Corresponding author for this work

Cardiovascular Sciences

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	739-741
Number of pages	3
Journal	Journal of Thrombosis and Thrombolysis
Volume	57
Early online date	15 Feb 2024
DOIs	https://doi.org/10.1007/s11239-024-02948-5
Publication status	Published - Apr 2024

Bibliographical note

Response to:
Sutton et al. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis. 2023 Jul;56 (1):137-146.[1]

Access to Document

10.1007/s11239-024-02948-5Licence: None: All rights reserved

Cite this

Buka, R., Nicolson, P., & Sutton, D. (2024). Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. Journal of Thrombosis and Thrombolysis, 57, 739-741. https://doi.org/10.1007/s11239-024-02948-5

Buka, Richard ; Nicolson, Pip ; Sutton, David. / Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. In: Journal of Thrombosis and Thrombolysis. 2024 ; Vol. 57. pp. 739-741.

@article{9207a4265d004239b126336be8d87924,

title = "Enoxaparin is not an oral factor Xa inhibitor.: Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate",

author = "Richard Buka and Pip Nicolson and David Sutton",

note = "Response to: Sutton et al. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis. 2023 Jul;56 (1):137-146.[1]",

year = "2024",

month = apr,

doi = "10.1007/s11239-024-02948-5",

language = "English",

volume = "57",

pages = "739--741",

journal = "Journal of Thrombosis and Thrombolysis",

issn = "1573-742X",

publisher = "Springer",

}

Buka, R , Nicolson, P & Sutton, D 2024, 'Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate', Journal of Thrombosis and Thrombolysis, vol. 57, pp. 739-741. https://doi.org/10.1007/s11239-024-02948-5

Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. / Buka, Richard ; Nicolson, Pip; Sutton, David.
In: Journal of Thrombosis and Thrombolysis, Vol. 57, 04.2024, p. 739-741.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Enoxaparin is not an oral factor Xa inhibitor.

T2 - Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

AU - Buka, Richard

AU - Nicolson, Pip

AU - Sutton, David

N1 - Response to: Sutton et al. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis. 2023 Jul;56 (1):137-146.[1]

PY - 2024/4

Y1 - 2024/4

U2 - 10.1007/s11239-024-02948-5

DO - 10.1007/s11239-024-02948-5

M3 - Comment/debate

SN - 1573-742X

VL - 57

SP - 739

EP - 741

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

ER -

Buka R , Nicolson P, Sutton D. Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. Journal of Thrombosis and Thrombolysis. 2024 Apr;57:739-741. Epub 2024 Feb 15. doi: 10.1007/s11239-024-02948-5